发明授权
- 专利标题: Anti-lymphotoxin-β receptor antibodies as anti-tumor agents
- 专利标题(中): 抗淋巴毒素-β受体抗体作为抗肿瘤剂
-
申请号: US11185373申请日: 2005-07-19
-
公开(公告)号: US07459537B2公开(公告)日: 2008-12-02
- 发明人: Jeffrey L. Browning , Werner Meier , Christopher D. Benjamin
- 申请人: Jeffrey L. Browning , Werner Meier , Christopher D. Benjamin
- 申请人地址: US MA Cambridge
- 专利权人: Biogen Idec MA Inc.
- 当前专利权人: Biogen Idec MA Inc.
- 当前专利权人地址: US MA Cambridge
- 代理机构: Lahive & Cockfield, LLP
- 代理商 Amy E. Mandragouras, Esq.; Cristin Howley Cowles
- 主分类号: C07K16/00
- IPC分类号: C07K16/00
摘要:
This invention relates to compositions and methods useful for activating LT-β receptor signaling, which in turn elicits potent anti-proliferative effects on tumor cells. More particularly, this invention relates to lymphotoxin heteromeric complexes formed between lymphotoxin-α and multiple subunits of lymphotoxin-β, which induce cytotoxic effects on tumor cells in the presence of lymphotoxin-β receptor activating agents. Also within the scope of this invention are antibodies directed against the lymphotoxin-β receptor which act as lymphotoxin-β receptor activating agents alone or in combination with other lymphotoxin-β receptor activating agents either in the presence or absence of lymphotoxin-α/β complexes. A screening method for selecting such antibodies is provided. This invention also relates to compositions and methods using cross-linked anti-lymphotoxin-β receptor antibodies either alone or in the presence of other lymphotoxin-β receptor activating agents to potentiate tumor cell cytotoxicity.
公开/授权文献
信息查询